China
China leads Asia Pacific in high-value oncology deals in 2020
China has 3,667 ongoing clinical trials for 1,761 oncological drugs as of 10 March.
China leads Asia Pacific in high-value oncology deals in 2020
China has 3,667 ongoing clinical trials for 1,761 oncological drugs as of 10 March.
Rise in ageing population and diseases drive APAC's MRI market
The population aged above 65 in China is projected to reach 247 million by 2030.
APAC emerged as second largest market for hospitals, outpatient centres
China’s medical insurance schemes will help improve healthcare access in the country.
Infrastructure initiatives boost traditional Chinese medicine production
Demand for traditional Chinese medicine is rising in developed economies.
Generic medications and Asia-Pacific health systems: A viable win-win-win strategy?
This article explains in greater detail the challenges faced by the generic drug manufacturing industry.
Ping An Good Doctor's revenue rose 35.5% to $1.06b in 2020
The company’s average daily consultations jumped 23.9% to 903,000.
111 rolls out mobile healthcare services in Northeast China
Baiyi Doctor Group will provide internet-based diagnosis and treatment.
Rising population boosts APAC's over-the-counter drugs market
In countries with high populations, patients rely on neighborhood chemists for medications.
China's online healthcare untouched by internet antitrust push
Shares of online healthcare firms soared despite new antitrust laws on internet companies.
APAC's sterilization equipment market on the rise as hospitals multiply
The region accounts for more than 20% of the market globally.
Aoyuan Healthy acquires 55% equity in Liantianmei for $101.72m
With this acquisition, Aoyuan holds 60% equity interest in the company.
Chinese pharma market to grow 3.2% this year
The Government’s efforts to cut drug spending will create challenges for international drugmakers.
HSBC releases China pharma market outlook for H2
Small cap companies with low valuations could outperform, but leading companies may provide more stable returns.
Sino Biopharma records $1,852m revenue in H1
Earnings per share were 5.2% higher than that of the same period last year.
Lee's Pharma announces H1 results
The group’s revenue is up 3.9% measured QoQ.
Viva Biotech buys 80% share of Langhua Pharma
The company expects to deliver more comprehensive end-to-end services through this acquisition.
China's healthcare spending to reach $49b by 2023
By then, China will account for 23% of the world’s healthcare spending.
Most Read
1. SGH and NNI study reveals connection between scoliosis and brainstem 2. Why rare disease policies are critical to ensure equitable access to treatment for rare disease communities in Southeast Asia 3. 3 in 5 novice nurses struggle with higher-complexity procedures 4. Synpaxe, tech giants foster GenAI in healthcare 5. EGH Campus in Bedok North to offer services before 2030 completionResource Center
Read Here
Advertise
Sign Up
Event News
Event News
Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi
![Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi]()
Co-Written / Partner
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
